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Evaluation of recombinant factor C assay for the detection of
divergent lipopolysaccharide structural species and
comparison with Limulus amebocyte lysate-based assays and a
human monocyte activity assay
Wondwossen Abate,1,* Anas A. Sattar,1 Jian Liu,2 Myra E. Conway3 and Simon K. Jackson1
Abstract
Purpose. The Limulus amebocytelysate (LAL) assay is widely used for the screening of lipopolysaccharide (LPS) in parenteral
pharmaceuticals. However, correlation of LPS in Gram-negative bacterial infections by LAL assay has been problematic,
partly due to the variable reactivity of different LPS structures. Recombinant factor C (rFC) has allowed the development of a
new simple, specific and sensitive LPS detection system (PyroGene). In this work, the potential of the new assay for detecting
various LPS structures has been investigated and compared with two LAL-based assays and a human monocyte
activity assay.
Methodology. The activity of the various LPS structures has been investigated by PyroGene and two LAL-based assays and a
human monocyte activity assay.
Results. The rFC assay detected most LPS structures in picogram quantities and the potency of E. coli, B. cepacia, Salmonella
smooth and Salmonella R345 LPS was no different when measured with PyroGene or LAL assays. However, the reactivity of
K. pneumoniae, S. marcescens, B. pertussis and P. aeruginosa LPS differed significantly between these assays. Importantly,
pairwise correlation analysis revealed that only the PyroGene assay produced a significant positive correlation with the
release of IL-6 from a monocytic cell line.
Conclusion. We conclude that the rFC-based assay is a good replacement for conventional LAL assays and as it correlates
significantly with IL-6 produced by a human monocyte cell line it could potentially be more useful for detecting LPS in a
clinical setting.
INTRODUCTION
Parenteral pharmaceutical products and medical devices
such as pacemakers, catheters and other invasive devices are
required to be free from pyrogenic contamination [1], as
potentially life-threatening septic shock could be elicited if
pyrogens are administered inadvertently to the human body
[2]. Bacterial endotoxin (lipopolysaccharide; LPS) is the
pyrogen of main concern to the pharmaceutical and medical
industries because it is the most common contaminant and
is stable and shows high pyrogenicity [3–5].
LPS, which is a complex glycolipid embedded within the
outer membrane of Gram-negative bacteria, is ubiquitous
and shows manifold biological activities [6]. It comprises a
conserved acylated disaccharide, known as lipid A, which is
attached to a core oligosaccharide moiety (Fig. 1a). The core
region is further extended by additional glycosylation to
give the O-specific antigen [7]. The nature and number of
sugars, as well as the number of repeat units within the O-
polysaccharide region, determine the serotype specificity of
each bacterial strain within a species. The biologically active
part of LPS, lipid A, also shows structural diversity due to
the pattern of substitution of the two phosphate groups on
lipid A, the type of fatty acids and the degree of acylation [7,
8]. Lipid A from E. coli LPS typically has a hexa-acyl struc-
ture (similar to the one shown in Fig. 1a), while LPS from
different Gram-negative bacteria may have different num-
bers and arrangements of acyl chains (Fig. 1b) [9].
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LPS is an important inflammatory molecule that has been
shown to induce responses in many different cell types [8].
Humans are extremely sensitive to endotoxin and nanomo-
lar quantities of LPS are sufficient to induce an acute fever
response [10] and sepsis [11]. The extremely high potency
of LPS in affecting biological systems, along with its
ubiquity and stability, have required the development of a
highly reliable, sensitive and quantitative test for the phar-
maceutical and medical industries [12].
Currently, the rabbit pyrogen test and the bacterial endo-
toxin test (BET), often referred to as the Limulus amebocyte
lysate (LAL) test, are prescribed by health authorities and
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Fig. 1. (a) Schematic diagram of lipopolysaccharide from Salmonella minnesota showing the main structural components. The regions
with truncation of the core sugars in the rough mutants Rb2 (S. minnesota R345) and Re (S. minnesota R595) are shown. GlcN, glucos-
amine; Kdo, ‘2-keto-3-deoxyoctulosonic acid’ (3-deoxy-D-manno-octulosonic acid); Hep, D-glycero-D-manno-heptose. Adapted from
Alexander and Rietschel [ 51]. (b) Lipid A structures of the LPS from the different Gram-negative bacteria used in this study. The table
shows the number, length and type of acyl chains for each lipid A species.
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pharmacopoeias to test parenteral medicinal products. The
adoption of the Russell and Burch 3R concept [13] by the
European Union in 1986 [14], which aims to refine, reduce
and replace the use of animals in diagnostic and research
testing, 14 led to a marked reduction in use of the rabbit
pyrogen test in subsequent years and the adoption of the
LAL test as an in vitro alternative pyrogen test for many
parenteral products.
The principle of the LAL assay is based on the observation
that endotoxin causes serine protease-mediated extracellular
coagulation of the haemolymph of the horseshoe crab [15].
The enzymatic components and the molecular events that
are responsible for the clotting cascade of Limulus polyphe-
mus and other related species (namely Tachypleus tridenta-
tus [16] and Carcinoscorpius rotundicauda [17]) are well
characterized (Fig. 2). Factor C, the first component of the
cascade, is a serine protease that is activated by endotoxin
binding [16]. The cascade, initiated by LPS, culminates in
the activation of the pro-clotting enzyme to its active form,
the clotting enzyme, which in turn acts on coagulogen to
convert it into the coaglulin clot (Fig. 2) [16, 18, 19]. The
kinetic chromogenic LAL assay uses a synthetic peptide-p-
nitroanaline substrate that is cleaved by the clotting enzyme,
resulting in a product that exhibits a yellow colour (Fig. 2).
The intensity of the yellow colour or the rate of colour for-
mation correlates with the concentration of LPS in the
assayed samples. The coagulation cascade of the LAL system
can also be activated via activation of factor G by fungal glu-
cans [20] (Fig. 2, upper right), although the activation of
factor C by LPS is many times more sensitive [21].
In addition, the LAL assay shows batch-to-batch fluctua-
tions due to seasonal and geographical differences in the
starting materials [12]. Furthermore, the dwindling horse-
shoe crab population, mainly due to extensive harvesting as
a bait for commercial fishing [22], habitat loss and pollu-
tion, mandates the conservation of this organism, as it has
important roles in the ecology of its marine habitat [2]. The
commercial exploitation of the horseshoe crab for the LAL
assay, therefore, adds to the threats to its populations [2,
12]. To overcome all these issues, an alternative source of
LAL assay was required.
This led to the production of factor C (FC) by recombinant
DNA technology. FC has been cloned and expressed in
Escherichia coli [23], yeast [23, 24] and mammalian cells
[25], and recombinant FC (rFC) is capable of strongly bind-
ing LPS. The production of an rFC has enabled the develop-
ment of a simple, specific and sensitive LPS detection assay
that could potentially replace routine LAL-based assays
(Fig. 2, upper left), particularly in cases where fungal con-
tamination might be high.
Despite the applicability of the LAL assay for the detection
of LPS from many bacterial sources, there has been no study
to investigate the reactivity of rFC with different LPS struc-
tures. The range and sensitivity of rFC to different LPS
structures will be important to determine before rFC-based
assays become more widely adopted for different test sam-
ples. Moreover, the comparison of LPS detection capabilities
between rFC and current LAL assays is also important to
ascertain. We believe this is the first study to determine the
reactivity of different LPS chemotypes with the PyroGene
(rFC) assay and then to compare the rFC-based assay with
two other commercial kinetic chromogenic LAL-based
assays in detecting LPS structures from various bacterial
species. Furthermore, the inflammatory potential of selected
rFC
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Fig. 2. The LPS reactive coagulation cascade system in the Limulus horseshoe crab that results in the formation of a coagulin gel.
The coagulogen chromogenic substrate and chromogenic product used in the LAL assays (adapted from [18, 28]) are shown. The
scheme also shows the activation of the LAL clotting system by factor G through interaction with fungal 1,3-b-D-glucan (top right). Acti-
vation of recombinant factor C (rFC) by LPS and subsequent reaction to form a fluorogenic product as used in the PyroGene assay is
shown at the top left.
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LPS structural species was determined by the induction and
release of IL-6 from a human monocytic cell line to allow
comparison and assess the clinical relevance of rFC-based
and LAL assays.
METHODS
LPS from Salmonella minnesota smooth strain, Salmonella
minnesota rough strain (R345), Escherichia coli O111:B4,
Klebsiella pneumoniae and Pseudomonas aeruginosa sero-
type 10 were purchased from Sigma-Aldrich (Poole, UK).
[‘Premium Grade’ (protein, nucleic acids <1%)]. LPS from
E. coli J5, Salmonella minnesota lipid A, Salmonella minne-
sota rough strain (R595), Bordetella pertussis and Francisella
tularensis were from List Biologicals Laboratories, Inc.
(Campbell, CA, USA) [‘Ultra Pure’ grade (protein, nucleic
acids <1%)]. LPS from Burkhoderia cepacia and Serratia
marcescens was extracted from bacteria and treated with
DNase and proteinase K as described previously by Bam-
ford et al. [26]. The Kinetic-QCL LAL assay kit, WinKQCL
V 3.0.1 software, pyrogene-free water, dilution tubes and
pipette tips were purchased from Lonza (Verviers, Belgium).
The PyroGene recombinant Factor C endotoxin detection
kit was kindly provided by Lonza (Verviers, Belgium).
The Endosafe Endochrome-K Kinetic LAL assay kit was
purchased from Charles River (Charleston, SC, USA). The
FLx800 TBIE fluorescence microplate reader and the ELx-
808 IUBWI spectrophotometer were supplied by Bio-Tek
Instruments (Bedfordshire, UK). The human monocytic cell
line, Mono-Mac 6 (MM6), was obtained from the German
Cell Collection (DSMZ, Braunschweig, Germany) and all
tissue culture consumables were purchased from Lonza
(Verviers, Belgium). A DuoSet ELISA kit for IL-6 ELISA
was obtained from R & D systems (Oxford, UK) and reverse
transcription RT-PCR kits and primers were purchased
from Invitrogen Ltd (Paisley, UK). An iCycler thermal
cycler was supplied by Bio-Rad Laboratories
(Hertfordshire, UK).
Cell lines
Mono-Mac 6 (MM6) cells were maintained in RPMI 1640
medium, supplemented with 200mM L-glutamine, 1% pen-
icillin/streptomycin, 10% (v/v) foetal bovine serum, 1mM
sodium pyruvate and 1% (v/v) non-essential amino acids.
The cells were seeded at a density recommended by the sup-
plier and grown at 37

C in humidified air and 5% CO2.
Measurement of cytokines at the protein and mRNA
levels
MM6 cells (5105 for protein and 2.5106 for the expres-
sion of mRNA) were incubated with various LPS structural
species for 4 h (RT-PCR) or 24 h (ELISA). The released IL-6
in the cell culture supernatants following stimulation with
various endotoxins was measured by ELISA using a DuoSet
ELISA kit, whereas the level of mRNA expression was mea-
sured by RT-PCR using an iCycler thermal cycler (Bio-Rad,
UK) according to the manufacturer’s instructions. The pri-
mers for IL-6 and the internal control GAPDH were
designed using OligoPerfectTM online software (http://tools.
invitrogen.com). The primers for IL-6 were forward 5¢-TAC
CCC CAG GAG AAG ATT CC-3¢, reverse 5¢-TTT TCT
GCC AGT GCC TCT TT-3¢ and GAPDH forward 5¢-ACA
GTC AGC CGC ATC TTC TT-3¢ and reverse 5¢-GAC AAG
CTT CCC GTT CTC AG-3¢.
Endotoxin detection assays
The PyroGene recombinant factor C endotoxin detection
end-point assay was performed as described in the manu-
facturer’s instructions and analysed using WINKQCL V
3.0.1 software. The sensitivity or gating setting of the
FLx800 TBIE reader for individual kits was also determined
as outlined by the supplier using WinKQCL software. The
assays were performed according to the manufacturer’s
instructions using WinKQCL V 3.0.1 software for
both Kinetic QCL (KQCL) and Endosafe Endochrome-
K assays.
The following US Pharmacopeia (USP) reference standard
endotoxin (RSE) (LPS from E. coli O55:B5) dilutions were
made: 0.01, 0.1, 1 and 10 EU ml 1 in each experiment as a
standard for all the assays. Since different LPS structures did
not have similar potency, i.e. endotoxin activity as measured
by LAL or rFC-based assays, their activity in a LAL- or rFC-
based assay is expressed using an endotoxin unit (EU). The
EU is the activity of a specific endotoxin preparation,
defined as one-fifth of the amount of E. coli O55:B5 endo-
toxin required to bring about the threshold pyrogenic
response when injected into man and rabbit on a per kilo-
gram basis (1 EU=100 pg of E. coli O55:B5 endotoxin) [27].
The amount of the various LPS structures and lipid A (from
Salmonella minnesota) that were tested in the LPS detection
assays varied from a picogram up to 50 ng, however, for
comparison the results were expressed as EU ng 1 of LPS
for both rFC-based and LAL assays.
Data analysis
Statistical comparisons among groups were determined by
Student’s t-test and one-way ANOVA, or Pearson’s correla-
tion using GraphPad PRISM software v 4.03 (GraphPad
Software, Inc).
RESULTS
Detection of various LPS structural species by rFC-
based assay
In the present work, the reactivity of 11 different LPS struc-
tural species and a lipid A portion with rFC were analysed
and the results from the rFC-based assay were compared
with those from two LAL-based assays. The rFC-based assay
is designed to detect the LPS potency in the range of 0.01 to
10 EU/ml, and this assay was able to detect all the LPS struc-
tures in picogram quantities, except for the lipid A and LPS
from F. tularensis (Fig. 3a). However, there is a significant
variation in the activity of the different LPS structures as
measured by this assay (Fig. 3a). The most rFC-reactive, i.e.
potent, LPS structure detected was LPS from K.
pneumoniae, while the LPS from F. tularensis was the least
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reactive of all the structures investigated in this work.
Indeed, on an equal-weight basis, the LPS from the most
active species (K. pneumoniae) was 35 687 times more reac-
tive than the least reactive LPS (F. tularensis). The assay was
only able to detect LPS from F. tularensis when its concen-
tration was greater than or equal to 50 ngml 1, considerably
higher than the amounts detected for the other species.
To investigate the detection of the different chemotypes of
LPS from the enteric bacteria, LPS from Salmonella smooth
type, R345 (Rb2), R595 (Re) and lipid A from Salmonella
(Fig. 1a), and smooth-type E. coli O111:B4 and E. coli J5
were used (Fig. 3a). Chemotypes containing the core sac-
charide region (Salmonella R345 and E. coli J5) showed no
marked difference in rFC reactivity compared with the
smooth strain chemotype. However, chemotypes with a
truncated core region (R595) and lipid A showed signifi-
cantly reduced potency. The mean reactivity of Salmonella
smooth-type LPS was 134 times greater than that of the
lipid A. This marked difference in rFC reactivity between
smooth- and rough-strain LPS chemotypes is probably due
to differences in solubility. It was previously suggested that
the detergent additives of the PyroGene assay buffer, Zwit-
tergent, makes lipid A more insoluble and unreactive [28].
To aid the solubility of lipid A and improve its reactivity
with rFC, lipid A was treated with triethylamine, which is a
known LPS dispersion agent [29], and Triton X-100, which
is also reported to increase the reactivity with factor C [30].
The activation of rFC by lipid A was doubled when triethyl-
amine at a concentration range of 0.01 to 0.2% was used
(Fig. 3b). The activity of the smooth LPS structures was also
slightly increased with low levels of triethylamine, but
higher concentrations of triethylamine (>0.1%) reduced its
activity. Likewise, when other LPS structures were treated
with triethylamine at a concentration of 0.01%, it either
slightly increased or had no effect on their activation of rFC,
but higher concentrations of triethylamine negatively
affected their activity (Fig. 3c). Treatment of samples which
contained lipid A with low concentrations of Triton X-100
also enhanced the reactivity of lipid A-spiked samples
(results not shown).
Comparison of rFC-based assay with LAL-based
assays
The reactivity of the rFC-based assay with LPS was com-
pared with that for two LAL-based assays provided by two
different suppliers. The rFC-based assay showed greater
sensitivity to a number of LPS from different organisms,
while it gave approximately equal sensitivity in the detection
of LPS from others (Fig. 4). The activity of LPS from E. coli
O111:B4, Burkholderia cepacia, Salmonella smooth and Sal-
monella rough (R345) when analysed by rFC-based assay
showed no significant difference compared with the LAL
assays (KQCL and Endosafe Endochrome-K assays)
(P=0.1392). There was no marked variation between the
rFC-based assay and KQCL in the detection of LPS from E.
coli J5, but the Endochrome-K assay gave a significantly
higher reading for this structure (P=0.0016).
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Fig. 3. The reactivity of different LPS structures as determined with
the rFC-based assay. (a) The activity of each LPS structure is
expressed as endotoxin units (EU)/ng of LPS (n=at least three indepen-
dent experiments conducted in duplicate). *P<0.05; ***P<0.001 vs LPS
from E. coli O111.B4. Effect of triethylamine on the reactivity of lipid A
(b) and E. coli O111.B4 (c). For the E. coli O111.B4 the reactivity of LPS
with triethylamine was normalized against the LPS without the addi-
tion of triethylamine. *P<0.05; ***P<0.001 versus LPS from E. coli O111.
B4.
5
The potency of LPS fromKlebsiella pneumoniae and S. marces-
cens measured by rFC-based assay was significantly higher
than that measured by KQCL and Endochrome-K (P=0.0001).
The potency of the LPS from P. aeruginosa and B.
pertussis was significantly higher when assayed by rFC-based
assay compared with the KQCL assay (P=0.0159 and
P=0.00001, respectively). However, the PyroGene (rFC) assay
was less sensitive to Salmonella R595 compared with the LAL
assays. The rFC-based assay also showed less reactivity to lipid
A (P=0.0007) and LPS from F. tularensis compared with
the KQCL assay (P=0.00001). The Endochrome-K assay was
the least sensitive of the three assays in detecting lipid A; it
only detected lipid A when the concentrations
were >10ngml 1. Furthermore, the effect of the concentration
gradient on these assays was also investigated by using the
three strains of E. coli LPS, namely O55:B5, O111:B4 and J5. A
dilution ranging from 1000 to 1 pgml 1 was prepared and
assayed. The results showed there is a classical linear relation-
ship between the activity from the individual assays and the
LPS concentrations in the concentration range that was tested
(see Fig. S1, available in the online SupplementaryMaterial).
Induction of IL-6 by various LPS structural species
The various LPS structures used to study the reactivity of
rFC were also investigated for their potential to induce IL-6
from a human monocyte cell line. The induction of IL-6 at
the mRNA and protein levels was studied after the cells
were stimulated with various LPS structures for 4 and 24 h,
respectively. The various LPS structural species when added
to the cells at equal concentrations induced a markedly dif-
ferent level of IL-6 (Fig. 5). Previous studies have shown
that production of IL-6 by MM6 cells in response to the LPS
used is almost completely blocked by polymyxin B, and that
MM6 cells are almost uniquely sensitive to LPS at the con-
centrations used here, indicating that activation of the cell
assay was due to LPS rather than other contaminants [31,
32]. A very high level of IL-6 was released from the cells
when they were stimulated with LPS from E. coli, K. pneu-
moniae, B. cepacia, Salmonella (both the smooth and rough
R345 chemotypes) and S. marcescens, and there was no
marked difference amongst these structures in the level of
IL-6 induction. However, LPS from these bacteria induced
significantly higher amounts of IL-6 compared with LPS
from B. pertussis, P. aeruginosa and lipid A. The level of IL-
6 mRNA induction following stimulation of the cells with
selected LPS structures for 4 h was also studied. The result
obtained from RT-PCR was very similar to the ELISA result
(data not shown). The rFC-based assay showed a significant
positive correlation with the induction and release of IL-6
from the monocyte cell line (r2=0.62, P=0.039) (Table 1). In
contrast, the KQCL and Endosafe Endochrome-K assays
showed a positive correlation with IL-6, but the correlation
was not significant, as shown in Table 1.
DISCUSSION
Because of its ubiquity and biological potency, LPS is the most
important contaminant of pharmaceutical products [3, 4, 33].
Human beings are extremely sensitive to endotoxin and its
effects range from fever to shock and death [2, 11, 34]. This
necessitated the development of a highly reliable, sensitive
quantitative test for the pharmaceutical and medical industries
to avert any potential risks [12]. The LAL-based assay has been
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used to detect endotoxin successfully from pharmaceuticals,
parenteral fluids, medical devices, water and foods [12], and
supplanted the time-consuming and expensive rabbit pyrogen
test [2]. However, several groups [1, 2, 20, 35, 36] have ques-
tioned the specificity and sensitivity of the LAL-based assay, as
the alternative pathway (factor G) can react with fungal con-
taminants (b-D-glucan) [20] and also give a positive result. In
addition, some LAL-reactive materials that co-purify with clot
proteins in the Limulus lysate may also give false-positive or -
negative results in some batches of LAL [20, 35]. Moreover,
the commercial procurement of the horseshoe crabs for LAL
assays might exacerbate ecological concerns regarding horse-
shoe crab populations, which are threatened with extinction
[2, 12].
A simple and rapid fluorimetric assay for the detection of
endotoxin that is based on rFC and overcomes the short-
comings of LPS detection based on clot proteins derived
from the haemolymph of horseshoe crabs has been recently
introduced [12]. In the present work, the ability of the rFC
assay to detect various LPS structural species and lipid A –
which vary in the length of their O-chain, core region, num-
ber and length of acyl chains, and presence or absence of
phosphate groups on their lipid A – was evaluated.
Although factor C has been shown to be uniquely sensitive
to LPS, in order to avoid any possible reactivity to potential
contaminants, highly purified commercial LPS was utilized,
and at the concentrations used (100 ngml 1) there was
minimal protein or nucleic acid. In addition, the rFC-based
method was compared with two other LAL-based assays in
the detection of these different LPS structures.
The rFC-based endotoxin assay is able to detect all of the
LPS structures in picogram quantities, with the exception of
LPS from F. tularensis and lipid A from Salmonella minne-
sota. Within the LPS structures, there is a striking range of
reactivity, where the most reactive LPS (from K. pneumo-
nia) is nearly 36 000 times more reactive than the least reac-
tive LPS (from F. tularensis). This difference could perhaps
arise from the structural characteristics of the lipid A moiety
of F. tularensis [37–39]. Unlike typical potent endotoxins,
which are equipped with two phosphate groups on the
diglucosamine backbone, F. tularensis lipid A has
no phosphate groups [39], or perhaps only one [38]. Using
synthetic lipid A analogues (LA-14-PP), Takada et al. [40]
showed that dephosphorylation of both phosphate groups
reduced the Limulus activity by approximately 32 000-fold.
This is almost the same degree of reduction in activity
that was noted in this study using the rFC-based assay. It is
worth pointing out here that factor C has also been reported
to interact with acidic phospholipids such as phosphatidyl-
glycerol and phosphatidylserine (but not with neutral phos-
pholipids) in a manner comparable to synthetic lipid A
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Fig. 5. The release of IL-6 induced by LPS structures. MonoMac 6 cells (5105 per well) were stimulated with the various LPS struc-
tural species at a concentration of 100 ngml 1 for 24 h (n = at least three independent experiments conducted in duplicate). The
released IL-6 in the cell culture supernatants was measured by ELISA using a DuoSet ELISA kit following the manufacturer’s instruc-
tions. *P<0.05 versus mean IL-6 production in LPS-stimulated cells.
Table 1. The Pearson’s correlation analysis matrix for the various LPS
structural species and lipid A for induction of IL-6 and pyrogenicity as
determined by PyroGene, KQCL and Endosafe Endochrome-K assays.
(n= at least three independent experiments conducted in duplicates).
PyroGene KQCL Endosafe IL-6
KQCL 0.34 – – –
P-value 0.14 – – –
Endosafe 0.41 0.93 – –
P-value 0.09 0.00 – –
IL-6 0.62 0.24 0.28 –
P-value 0.04 0.27 0.23 –
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analogues [19, 41, 42]. Therefore, it could be speculated that
electrostatic interaction is very important for the binding
and activation of factor C by LPS, and the reduction of neg-
ative charge due to lack of the phosphate groups could
potentially affect this interaction. The absence of phosphate
groups on the lipid A of F. tularensis might also indirectly
affect the interaction with factor C due to poor solubility of
the LPS species in the reagent mixture [40].
It has been demonstrated that the nature of the acyl groups
linked to the diglucosamine backbone of lipid A plays a key
role in the potency of lipopolysaccharide activation of factor C
[19, 40, 43]. The low reactivity of the LPS from F. tularensis
could thus be further explained by its significant deviation in
terms of the number and chain length of the fatty acids on lipid
A. F. tularensis lipid A is tetraacylated with three C-18 and a
C-16 fatty acid [38, 39], resembling less potent lipid A struc-
tures from Helicobacter pylori and Porphyromonas gingivalis
[44, 45] (as assessed by their potential in inducing pro-inflam-
matory cytokines from macrophages), while a typical biologi-
cally potent endotoxin has six C-12 to C-14 acyl chains.
Therefore, we would expect the reactivity of the LPS of Helico-
bacter pylori and Porphyromonas gingivalis to be similar to that
of F. tularensis. Using synthetic lipid A and its
analogues, Kanegasaki et al. [43] also showed a significant
reduction in Limulus activity when the number of fatty
acids was reduced from six to four.
The low reactivity of the lipid A of Salmonella minnesota in
all assays could be caused by its low solubility in aqueous
medium. Furthermore, there is a report [28] which claims
that lipid A is probably made more insoluble and unreactive
in the presence of Zwittergent, which is a detergent additive
of the rFC PyroGene Assay buffer. This detergent is added
to assay buffer to disperse the LPS aggregate and make it
more reactive to rFC. Since lipid A and lipid A-rich endo-
toxins are most likely to occur in naturally contaminated
solutions, the chance of missing these when using buffer
containing Zwittergent as a detergent could be high,
although the spike recovery with the O-antigen rich endo-
toxin results appears to be acceptable [21]. The solubility of
lipid A was enhanced using triethylamine, which is a known
LPS dispersion agent [29], and Triton X-100, which is also
reported to increase the activity of factor C [19]. It is not
known why the kinetic chromogenic LAL assay was more
sensitive to F. tularensis and lipid A, but it may be due to
differences in the buffer contents which aid the solubility of
more hydrophobic LPS structures. This suggestion is sup-
ported by the results using less soluble LPS from Salmonella
R595, which also gave a higher reactivity with the KQCL
LAL assay than the PyroGene rFC-based assay. However,
the more soluble penta- and hexa-acylated LPS structures
that were tested in this study were seen to be at least as
potent, if not more potent, when assayed by rFC-based
assay compared with the LAL-based tests.
Evaluation of assays that use non-human in vitro systems
(i.e. rFC or LAL) to assess potential human health risks
requires that comparisons be made with systems that use
human cells. Production of inflammatory cytokines, such as
IL-6, form a human monocyte cell line, MonoMac 6
(MM6), which has been shown to be a good model of
inflammatory potential in humans [46–48]. This cell line
expresses all the receptor components for LPS signalling
and is phenotypically and functionally similar to human
peripheral blood monocytes [32, 49]. Several investigators
[46–48] have also tried to use this cell line as an in vitro test
for pyrogens. Moesby et al. [50] made a comparative study
of MM6 cells with isolated mononuclear cells and the LAL
assay in respect of their potential to detect pyrogens. IL-6
was the preferred readout in the present project, since IL-6
is, in contrast to IL-1b or TNF-a, released entirely into the
cell-conditioned medium, allowing its complete estimation
[1], and this cytokine has been shown to be released by low
levels of LPS [47]. IL-6 is also the main endogenous pyrogen
in humans and experimental animals and thus shows a bet-
ter correlation with the pyrogenic activity of LPS in the
blood. The various LPS structures used at a concentration of
100 ngml 1 in the present study induced a significant level
of IL-6 from MM6 cells. Previous studies have shown that
MM6 cells are very sensitive to LPS [31, 32] and that com-
pared with LPS, putative pyrogens from Gram-positive
organisms are much less potent inducers of cytokines in
MM6 cells [46]. Moreover, in studies to identify microbial
contaminants in biological products using MM6 cells and
HEK293 cells transfected with different TLRs, only MM6
cells and HEK293 cells transfected with TLR4 responded to
LPS [34]. Therefore, MM6 cells are useful models for assess-
ing cell responses to LPS and our results with MM6 cells
with LPS at the concentrations used in the current work are
unlikely to be due to non-LPS contaminants. The same LPS
structures also produced significant activity in the rFC-
based assay and there was a significant positive correlation
between rFC and the MM6 cell system (r2=0.62, P=0.039).
This suggests that rFC may react to lipid A/LPS structural
variations in a similar manner to the MD-2–Toll-like recep-
tor 4 receptor of the host immune system and, theoretically,
it would be a useful assay for the assessment of LPS as a
potential biomarker of Gram-negative bacterial infections
and sepsis.
In conclusion, the rFC-based assay can be a viable alterna-
tive assay for the detection of endotoxin for pharmaceuti-
cals, medical devices, water and foods, and could replace
LAL-based assays and preclude the need to harvest horse-
shoe crabs, which are considered to be ‘living fossils’, and
so contribute significantly to their conservation.
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